Q1 EPS Estimate for Abeona Therapeutics Lowered by Analyst

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Investment analysts at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a note issued to investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn $0.04 per share for the quarter, down from their prior forecast of $0.05. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share.

A number of other equities analysts have also issued reports on the company. Wall Street Zen lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Stifel Nicolaus decreased their price target on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Finally, Oppenheimer increased their price target on Abeona Therapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Abeona Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $19.50.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $6.91 on Tuesday. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.54. The firm has a market capitalization of $353.49 million, a price-to-earnings ratio of 9.87 and a beta of 1.55. The business has a 50 day simple moving average of $6.24 and a 200 day simple moving average of $5.76. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.90 and a quick ratio of 4.90.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $2.10. The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million.

Insider Activity at Abeona Therapeutics

In other news, Director Mark Alvino sold 13,093 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the completion of the sale, the director owned 77,252 shares in the company, valued at approximately $452,696.72. This represents a 14.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joseph Walter Vazzano sold 25,411 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $148,908.46. Following the sale, the chief financial officer owned 479,168 shares of the company's stock, valued at $2,807,924.48. This trade represents a 5.04% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 231,626 shares of company stock worth $1,430,587. 6.90% of the stock is owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Boone Capital Management LLC purchased a new stake in shares of Abeona Therapeutics during the second quarter worth $7,126,000. Geode Capital Management LLC raised its holdings in shares of Abeona Therapeutics by 129.1% during the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company's stock worth $6,282,000 after acquiring an additional 623,243 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Abeona Therapeutics by 255.6% during the second quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company's stock worth $4,721,000 after acquiring an additional 597,373 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.